« Return to News | Drug Sponsors

GSK signs two-year pact with MolMed

Monday, August 8, 2011 11:49 AM

GlaxoSmithKline's efforts to tackle a rare and often deadly immune deficiency are making progress following a deal signed with Italy's MolMed, according to PharmaTimes.

In October last year, GSK linked up with San Raffaele Telethon Institute, gaining an exclusive license to an investigational gene therapy for ADA-SCID (adenosine deaminase deficiency – severe combined immune deficiency), commonly referred to as ‘bubble boy disease’. Now the drugs giant has signed a two-year, 5.5 million euro deal with MolMed which will develop a production process for the gene therapy which is in late-stage trials.

ADA-SCID is caused by a mutation in a single gene which prevents the body from producing the ADA enzyme. However, it has been possible to develop a therapy by inserting, through gene transfer technology, the correct form of the gene into the patient’s own stem cells derived from their bone marrow.

The disease affects around 350 children worldwide. Patients are unable to mount their own defense against foreign organisms so without specialist intervention are at risk from life threatening infections. A bone marrow transplant (if a suitable donor can be found) is currently the best treatment option available but because gene therapy uses the patient’s own cells there is much less risk of immune rejection.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.